No Data
No Data
Sector Update: Health Care Stocks Advance Late Afternoon
Sector Update: Health Care
ALX Oncology Announces Encouraging Final Results From Phase 1 Trial Evaluating Evorpacept in Combination With Standard-of-Care Treatment in Patients With B-cell Non-Hodgkin Lymphoma
Express News | ALX Oncology Announces Encouraging Final Results From Phase 1 Trial Evaluating Evorpacept in Combination With Standard-of-Care Treatment in Patients With B-Cell Non-Hodgkin Lymphoma
ALX Oncology Falls on Mid-stage Trial Setback for Lead Asset
ALX Oncology Announces ASPEN-03 And ASPEN-04 Phase 2 Trials Evaluating Evorpacept With A Checkpoint Inhibitor For The Treatment Of Head And Neck Cancers Did Not Meet Primary Endpoints